FDA accepts Topaz NDA

The US Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Topaz Pharmaceuticals...

The application is for the use of ivermectin topical cream as a treatment for head lice infestations in children and adults. Topaz CEO and President Robert Radie said the filing represented the Pennsylvania company's transition from the development phase towards commercialisation. More...